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•	 Prediction of antigenic epitopes for Brucella membrane proteins.
•	 Production of designed polypeptide in E. coli BL21 (DE3).
•	 Interaction of produced polypeptide with Brucella	specific	antibodies.
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ABSTRACT
Brucellosis is one of the most common diseases in humans and it has a worldwide spread. 
The design and production of newly synthesized proteins can be served as a goal for the 
rapid	and	accurate	detection	of	brucellosis.	To	this	aim,	finding	the	antigenic	epitopes	is	
the	first	step	to	design	a	diagnostic	method.	In	this	study,	the	epitope	mapping	procedure	
was carried out by IEDB analysis resource using Flagellin and Porin amino acid 
sequences. The selected sequences were linked by GS linkers and cloned into pET26b 
vector.	After	confirmation	of	the	expressed	recombinant	polypeptide	by	western	blotting,	
it was immunologically analyzed by gel diffusion assay. The SDS PAGE and western 
blot	 analysis	 confirmed	 the	 27	 KDa	 polypeptide	 production	 and	 observing	 an	 arc	 in	
gel diffusion test demonstrated the precipitation of serum antibodies and the presence 
of	 specific	 antigen	 complexes.	 The	 results	 showed	 that	 the	 recombinant	 polypeptide	
produced in E. coli BL21, could interact with antibodies present in Brucella immunized 
sheep serum.
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Brucellosis is one of the most common human diseases 
and it has a worldwide spread. This bacterium is 
transmitted from human to human and from animal to 
human beings, mainly through infected dairy crops. 
Among the species of Brucella, four species of Brucella 
melitensis, B. Abortus, B. Suis and B. Canis are the 
most important causes of human disease (Franco et al., 
2007).	Brucellosis	is	considered	as	a	health	and	economic	
problem in many countries of all parts of the world. It 
is an endemic infection worldwide and is prevalent in 
developing countries (Moreno and Moriyón, 2002). 
Human brucellosis is also distributed equally around Iran. 
Brucella, as an intracellular microbial pathogen prefers 
monocytes and macrophage cells. The bacterium contains 
aggressive genes that are important in host interaction 
and pathogenesis. Dependent secretion encoding genes 
(BAB_RS 31620) of the Secretion systems III, IV, and 
V are involved in binding, infectivity, and hemolysis 
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of Brucella. In addition, the availability of the genome 
sequence of the Brucella species provides an opportunity 
for aggressive mechanisms. Some features of outer 
membrane proteins in Brucella are quite distinct and play 
an important role in determination of its characteristics. 
Brucella membrane proteins structure are divided 
according to their size.  The outer membrane protein 
(OMP) with a molecular mass of 36 kDa is a porin which 
is	 the	first	candidate	 for	protection	against	 the	 infection	
(Pathak	et	al.,	2017).	In	addition,	 the	membrane	protein	
antigens in Brucella can induce both cellular and humeral 
immunity	systems	(Van	De	Verg	et	al.,	1996;	He,	2012).
The production of engineered newly synthesized 
proteins	 from	 several	 antigenic	 and	 exposed	 structural	
proteins can be served as a goal for the rapid and 
accurate detection of brucellosis (Seco-Mediavilla et 
al.,	2003;	Yin	et	al.,	2016).	Identification	and	evaluation	
of the different antigens of Brucella species have a key 
role in promotion of the accurate and timely diagnosis 
programs. In the present research, the production and 
purification	of	antigenic	epitopes	of	the	porin	and	flagellin	
proteins of Brucella melitensis were carried out which 
are the most important antigenic structural markers of 
this bacterium and will be evaluated in ELISA test for 
sheep and human Brucellosis in future by the present 
researchers.
Materials and Methods
Prediction of immunodominant epitopes and construction 
of the Polypeptide sequence 
Initially, amino acid sequences of the Flagellin and 
Porin of Brucella melitensis	 were	 found	 from	 Expasy	
and	NCBI	data	Banks	(Porin	BAB/RS19100,	membrane	
protein BAB/RS23045). The epitope mapping procedure 
was employed with IEDB analysis Resource (http://
tools.immuneepitope.org/main/) and linear epitopes from 
Flagellin and Porin protein sequences were predicted. 
Antigenicity, solubility, and accessibility of both proteins 
were the most important factors for analysis. The 
predicted Flagellin and Porin epitopes sequences were 
linked	by	flexible	linkers	(marked	sequences).	Then,	the	
fragment was optimized with E. coli codon usage and the 
sequence of interest with start, stop, and S tag peptide 
codons was synthesized and constructed in to pET 26b 
vector	(Bioneer,	Korea).	




























Recombinant production of designed polypeptide 
E. coli BL21 strain was transformed with the recombinant 
plasmid. The single colonies of E. coli BL21(DE3) 
containing the recombinant plasmids were grown in LB 
medium	with	30	µg/ml	kanamycin	at	37°C	to	reach	 the	
density of OD600=0.6. Then, IPTG 1 mM was added to 
induce	 the	 expression	of	 the	 recombinant	protein.	After	
3	 hours	 of	 cultivation	 at	 37°C,	 the	 bacterial	 cells	 were	
harvested via centrifugation at 8,000 rpm for 5 min.
The recombinant protein with the S-tag peptide was 
subjected to SDS-PAGE on a 10% polyacrylamide gel. 
The	samples	were	mixed	with	a	2X	loading	buffer	(125	
mM Tris, 20% Glycerol, 4% SDS and 0.01% bromophenol 
blue at pH 6.8). The gels were stained with Coomassie 
brilliant blue R-250. For analysis of the polypeptide by 
western blotting, the recombinant proteins were separated 
on a 10% polyacrylamide gel and were electrophoretically 
transferred	 to	 a	 nitrocellulose	 membrane	 (Whatman,	
UK).	 	 The	 membrane	 was	 incubated	 with	 a	 1:2000	
dilution of the ALP (alkaline phosphatase)-labeled anti-
Stag	monoclonal	antibody	(Abcam,	UK).	The	NBT/BCIP	
substrate solution (Roche, Germany) was used as the ALP 
substrate to visualize the immune reactivity.
Purification of the recombinant polypeptide 
After	confirmation	of	the	produced	recombinant	S-tagged	
polypeptide,	 it	was	 purified	 by	 affinity	 chromatography	
using S-tag resin (Novagen, USA). The bacterial pellet 
was suspended in 5 ml of denaturing buffer (6 M Urea, 20 
mM NaH2PO4, and 500 mM NaCl at pH 8.0) and lysed with 
45
Expression of the antigenic epitopes of Brucella melitensis
S. Sharghi et al. / TPPS 2017 2 (1) 44-48
46
sonication on ice. After carrying out the chromatography 




Immunological evaluation of the pofla polypeptide
The recombinant polypeptide was evaluated by 
Ouchterlony test (Gel Diffusion) for polypeptide 
confirmation	and	specific	interaction	with	infected	serum	
antibodies	(Lord,	Rolo	et	al.	1989).	A	total	of	100	positive	
sheep sera suspect to brucellosis (or with abortion) which 
had positive coombs tests and 100 healthy sheep sera from 
the veterinary organization were prepared. Gel diffusion 
was	set	up	with	agarose	1%	and	1X	PBS.		
Results and Discussion
Design and characterization of Pofla polypeptide
 
Designed	 amino	 acid	 sequence	 of	 Pofla	 polypeptide	 by	
Epitope mapping in IEDB server, together with upstream 
and	downstream	parts	has	the	molecular	weight	of	27	kDa.	
The	 Pofla	 obtained	 sequence	 was	 analyzed	 by	 several	
servers like Jpred4, PSIPRED, and ProtParam which 
showed that the secondary structure of the polypeptide 
had	 both	 alpha	 helix	 and	 beta	 stranded	 sheets,	 proper	
stability, and god solubility in water. pI of recombinant 
polypeptide was calculated as 3.84 (Fig.1).
Pofla polypeptide production
The	 designed	 658bp	 DNA	 fragment	 coding	 the	 Pofla	
polypeptide was synthesized into pET26b vector. The 
desired	 plasmid	 sequence	 was	 confirmed	 using	 PCR	
(Fig. 2).
The	designed	polypeptide	was	expressed	in	E. coli and 
approved	by	the	SDS-PAGE	(Fig.	3a),	and	Western	blot	
analysis with S tag monoclonal antibody (Fig. 3b).
Polypeptide-antibody interaction analysis by gel diffusion 
test
Antigen-antibody	complex	precipitation	was	assessed	by	
Ouchtelony test (Fig. 4). These results indicated that there 
are serum antibodies against of these Brucella	 specific	
immune-determinant epitopes which could recognize the 
bacterial	antigens,	specifically.	Also,	it	has	confirmed	the	
efficient	folding	of	pofla	polypeptide	produced	in	E. coli.













Figure 2. PCR product electrophoresis on 1% agarose gel. 658bp 
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Conclusion
Brucella species are gram-negative bacteria, the 
optional intracellular bacteria that can cause infection in 
many animals and human species that is economically 
and	 hygienically	 important	 (Guilloteau	 et	 al.,	 1999).	
Brucella in animals is preferably placed in reproductive 
organs and embryonic tissues, which causes abortion 
and	 infertility,	 followed	 by	 significant	 economic	 losses	
(Corbel, 2006). The important concept, in the way to 
achieve	 efficient	 diagnostic,	 preventive,	 and	 therapeutic	
method,	 is	 the	finding	of	effective	antigenic	epitopes	 to	
timely and accurately detect the brucellosis. To this end, 
an immunological diagnosis and evaluation of various 
antigens of the Brucella cell should be performed. From 
the preceding research, it can be concluded that Flagellin 
and porin proteins of Brucella could be a good candidates 
to design a laboratory diagnostic kit. The results obtained 
from this study showed that Brucella	external	membrane	
proteins,	widely	identified	as	immunogenic	and	antigenic	
epitopes, can be useful targets in generating diagnostic 
and vaccine-producing antigens. In traditional methods 
for the production of Brucella natural proteins, a bulk 
culturing	is	prepared	and	the	proteins	are	purified	from	the	
whole culture, whose both processes are very laborious 
and dangerous procedures. Also, the obtained amount 
of	 specific	 proteins	 of	 the	 bacteria	 outer	 membrane	 is	
not enough for following process and thus, is not cost-
effective. To control brucellosis, vaccine production and 
detection of infection are the most important disease 
control programs. Therefore, the prevention of human 
brucellosis is dependent on the disease control in animals. 
Vaccines for the prevention of the animal brucellosis 
containing live strain are available, but there is no approved 
recombinant vaccine for human protection. Therefore, 




the present study, we obtained the antigenic epitopes of 
flagellin	 and	 porin	 proteins	 of	 Brucella melitensis and 
designed a recombinant fused polypeptide with S-tag 
sequence. In order to produce this protein, the plasmid 
encoding the desired gene successfully transferred into 
E. coli BL21 (DE3), and a protein with the molecular 
weight	 of	 	 27	 kDa	 was	 expressed	 being	 confirmed	 on	
the	 SDS-PAGE	 and	 verified	 by	Western	 blotting	 using	
a conjugated monoclonal S-tag antibody.  Finally, the 
purified	 recombinant	 polypeptide	 was	 confirmed	 by	
the gel diffusion against the infected sheep serum that 
confirmed	 the	 specificity	of	 the	 selected	 epitopes	 in	 the	
designed	 polypeptide.	 Therefore,	 as	 a	 final	 conclusion,	
this polypeptide which has been designed by IEDB server 
from	porin	 and	flagellin	 proteins	 of	Brucella melitensis 
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Figure 3. The	 Western	 blot	 (a)	 and	 SDS	 PAGE	 (b)	 analysis	 of	
27KDa	 pofla	 polypeptide.
Figure 4.	 Antigen-Antibody	 complexes	 precipitation	 in	 Gel	
Diffusion test (a), Negative control (b).
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